Publications by authors named "Peter L Johansson"
Objective: In myeloproliferative neoplasms (MPN), interferon-alpha (IFN-α) is an effective treatment with disease-modifying properties but currently with no clear predictors of treatment outcome. Recent genomewide association studies in chronic hepatitis C have found a strong influence of genetic polymorphism near the IL28B (IFNL3) gene in response to IFN-α treatment. In this study, we sought to evaluate the prognostic impact of IL28B rs12979860, rs8099917, and rs12980275 on IFN-α treatment response in myeloproliferative neoplasms.
View Article and Find Full Text PDFArticle Synopsis
- Myelofibrosis (MF) is a serious blood cancer that leads to low blood cell counts and various symptoms, especially in patients with low platelet levels (thrombocytopenia).
- A study examined the quality of life and symptom severity in 418 MF patients, showing that those with thrombocytopenia had significantly worse symptoms and higher total symptom scores compared to those without.
- Patients with severe thrombocytopenia faced even higher risks of anemia and other complications, highlighting the need for improved treatment options for these individuals.
Article Synopsis
- - The study investigates how gender affects the symptoms and complications of myeloproliferative neoplasms (MPNs), which include polycythemia vera, essential thrombocythemia, and myelofibrosis, involving 2,006 patients.
- - Findings reveal that females are more likely to experience severe and frequent symptoms compared to males, despite similar quality of life scores, with women particularly reporting worse abdominal and microvascular symptoms.
- - Males, on the other hand, are more likely to have polycythemia vera and experience complications such as thrombocytopenia and greater red blood cell transfusion requirements, along with shorter disease duration.
Article Synopsis
- Polycythemia vera (PV) is a condition linked to serious health issues and unpleasant symptoms, and JAK inhibitor therapy has shown promise for patients who have previously used hydroxyurea (HU) and experience symptoms like splenomegaly.
- A study evaluated 1,334 PV patients to investigate how previous HU use, phlebotomy needs, and splenomegaly contribute to symptom severity.
- Findings revealed that each of these factors is associated with a significant symptom burden, and having more than one feature increases the severity of symptoms, highlighting that patients with any of these issues experience considerable discomfort.
Symptom burden in myeloproliferative neoplasms (MPNs) is heterogeneous even among patients within the same MPN diagnosis. Using cluster analysis from prospectively gathered symptom burden data in 1470 international patients with essential thrombocythemia (ET), polycythemia vera (PV), or myelofibrosis (MF), we assessed for the presence of clusters and relationship to disease features and prognosis. In MF (4 clusters identified), clusters significantly differed by Dynamic International Prognostic Scoring System (DIPSS) risk (P < .
View Article and Find Full Text PDFArticle Synopsis
- The study focused on developing an abbreviated symptom score (MPN-SAF TSS) to assess and track the most relevant symptoms experienced by patients with myeloproliferative neoplasms (MPNs), aiming to improve treatment outcomes.
- Analysis included 1,408 MPN patients and revealed significant differences in symptom scores across different MPN subtypes, with a strong correlation to overall quality of life and internal consistency.
- The MPN-SAF TSS showed potential as a reliable tool for measuring symptom burden in MPN patients, making it valuable for evaluating treatment responses in future studies.
Recently, a Jak2V617F mutation has been described in the vast majority of patients with polycythemia vera (PV) as well as in subsets of patients with essential thrombocythemia (ET) and idiopathic myelofibrosis (IMF). The question arises whether this mutation is observed in those patients with ET and IMF who have also displayed previously described molecular markers, notably the ability to form endogenous erythroid colonies (EECs), overexpression of polycythemia rubra vera 1 (PRV-1), and decreased c-Mpl expression. We therefore analyzed the Janus kinase 2 (Jak2) DNA sequence, EEC growth, PRV-1 expression, and c-Mpl (myeloproliferative) levels in a cohort of 78 myeloproliferative disorder (MPD) patients (42 ET, 22 PV, and 14 IMF).
View Article and Find Full Text PDFC-Mpl and PRV-1 expression was measured in a cohort of 48 patients with essential thrombocythemia (ET). A retrospective analysis was conducted to asses whether the presence of one or both markers correlates with a higher risk of developing thromboembolic complications. In this cohort, PRV-1 overexpression was associated with a significantly increased risk of thrombosis, whereas decreased c-Mpl expression was not.
View Article and Find Full Text PDFThe diagnosis of polycythaemia vera (PV) has been established upon sets of clinical criteria, which require the presence of absolute erythrocytosis (AE). The most recent clinical criteria for PV, published by the World Health Organization (WHO) in 2001, also required AE, and stated that the measured red cell mass (RCM) could be replaced by a surrogate marker for AE; a haemoglobin (Hb) value of >18.5 g/dl in males and >16.
View Article and Find Full Text PDF